(Q44120797)

30 November 2017

Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma (English)

1 reference

30 November 2017

1 reference

3

Tin Aung

1 reference

30 November 2017

Paul T K Chew

1

1 reference

PubMed ID

12204708

30 November 2017

Por T Hung

series ordinal

2

1 reference

PubMed ID

12204708

30 November 2017

language of work or name

1 reference

1 August 2002

1 reference

30 November 2017

Survey of Ophthalmology

1 reference

30 November 2017

47 Suppl 1

1 reference

30 November 2017

S125-8

1 reference

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Epidemiology of angle-closure glaucoma: prevalence, clinical types, and association with peripheral anterior chamber depth in the Egna-Neumarket Glaucoma Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Issues in the epidemiology and population-based screening of primary angle-closure glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Glaucoma in Mongolia. A population-based survey in Hövsgöl province, northern Mongolia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Provocation and Mechanism of Angle-Closure Glaucoma After Iridectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Clarifying the nomenclature for primary angle-closure glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Persistent symptoms after peripheral iridectomy for angle-closure glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Number of people with glaucoma worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

Provocation and medical treatment in post-iridectomy glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900305-3

7 January 2021

10.1016/S0039-6257(02)00305-3

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12204708